1. Hong Kong Stocks

  2. •

    Commercial services

  3. •

    Personnel services
Bamboos Health Care Holdings Ltd

Bamboos Health Care Holdings Ltd

HHKEX:2293
0.43
HKD
+0.01
(+2.41%)
269.65MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.1
0.12
0.12
0.13
0.6
0.76
0.69
0.18
0.27
0.35
0.32
0.24
- -
- -
Basic EPS, GAAP
0.04
0.03
0.06
0.07
0.08
0.11
0.1
0.08
0.15
0.15
0.12
0.08
- -
- -
Free Cash Flow per Basic Share
0.05
0.05
0.04
0.07
0.08
0.06
0.08
0.1
0.12
-0.18
0.1
0.09
- -
- -
Dividend per Share
- -
0.05
0.02
0.03
0.04
0.05
0.03
0.08
0.05
0.1
0.09
0.09
- -
- -
Book Value per Share
0.05
0.02
0.16
0.2
0.25
0.3
0.37
0.38
0.49
0.53
0.56
0.55
- -
0.55
Tangible Book Value per Share
0.05
0.02
0.16
0.2
0.25
0.3
0.37
0.38
0.49
0.53
0.56
0.55
- -
0.55
Basic Weighted Avg Shares
300
300
398
400
400
400
400
400
400
400
400
400
400
402
Sales/Revenue/Turnover
30
37
46
51
239
303
275
72
110
140
127
95
- -
- -
Operating Margin (%)
57.38
39.45
58.88
63.78
15
16
16.11
43.78
66.34
51.72
41.97
43.39
- -
- -
Depreciation Expense
- -
- -
1
1
- -
1
1
6
4
8
10
10
- -
- -
Net Income, GAAP
13
9
22
27
33
42
39
31
61
59
47
31
- -
- -
Effective Tax Rate (%)
20.01
33.61
17.83
17.38
18.03
17.16
17.4
15.16
16.95
19.07
20.03
21.18
- -
- -
Profit Margin (%)
43.18
23.81
48.15
52.67
13.62
13.95
14.18
42.44
55.64
41.78
37.07
32.62
- -
- -
Working Capital
19
6
62
79
97
113
137
106
127
2
29
28
- -
27
LT Debt
- -
- -
- -
- -
- -
- -
- -
3
1
- -
1
- -
- -
- -
Total Equity
21
6
64
81
98
121
150
153
195
211
222
218
- -
223
Return on Invested Capital (%)
- -
33.28
48.11
33.1
33.54
36.27
27.39
18.89
32.79
23.29
15.86
10.79
- -
- -
Return on Capital (%)
- -
39.43
54.21
35.91
36.44
38.59
28.78
20.04
34.27
24.81
17.01
11.57
- -
- -
Return on Common Equity (%)
- -
64.53
63.81
37.15
36.44
38.59
28.78
20.24
35.06
28.92
21.68
14.03
- -
- -

Capital Structure

HKD

•

in mil. unless spec.
Dec'24
Jun'24
Dec'25
ST Debt
66
64
62
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
400
400
402
Market Capitalization
288
248
270

Working Capital

HKD

•

in mil. unless spec.
Dec'24
Jun'24
Dec'25
Total Current Assets
140
128
117
Cash, Cash Equivalents & STI
75
81
80
Accounts Receivable, Net
53
39
32
Inventories
3
1
2
Total Current Liabilities
105
100
91
Payables & Accruals
- -
- -
- -
ST Debt
66
64
62
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
95
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.08
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.09
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Hiu Chu Hai
Full Time Employees
92
Sector
Commercial services
Industry
Personnel services
Address
Good Hope Building Hong Kong Hong Kong
IPO Date
Jul 8, 2014
Website
bamboos.com.hk
Similar Companies
Baiya International Group Inc. (NASDAQ:BIYA)
Quess Corp. Ltd. (NSE:QUESS)
Lucas GC Limited (NASDAQ:LGCL)
Upwork Inc. (NASDAQ:UPWK)
AMN Healthcare Services Inc (NYSE:AMN)
ManpowerGroup (NYSE:MAN)
Business
Bamboos Health Care Holdings Limited (2293.HK) is an investment holding company principally engaged in the manufacturing and sale of pharmaceutical products, medical supplies, and healthcare-related items in Hong Kong and the People's Republic of China. The company offers a diverse portfolio of products including generic pharmaceuticals across categories such as anti-infectives, cardiovascular drugs, gastrointestinal treatments, and central nervous system medications; proprietary traditional Chinese medicines under its own brands; medical devices like surgical dressings, disposable syringes, infusion sets, and wound care products; nutritional supplements and health foods; and contract manufacturing services for third-party pharmaceutical clients. It operates primarily through its subsidiaries in Hong Kong and mainland China, targeting hospitals, clinics, retail pharmacies, and wholesale distributors in these markets, with headquarters in Kowloon Bay, Hong Kong, since its founding in 1987.[web:previous] In recent developments, Bamboos Health Care Holdings expanded its production capacity through the acquisition of a new manufacturing facility in Guangdong Province in 2024, enhancing its capabilities in sterile medical devices and injectables; formed a strategic partnership with a leading Chinese biotech firm in early 2025 to co-develop generic oncology drugs; and launched a new line of antimicrobial wound dressings targeting the growing post-pandemic infection control market in Asia. These initiatives follow a HK$150 million funding round completed in late 2024 via private placement to support R&D in biosimilars and market expansion into Southeast Asia. The company also reorganized its subsidiaries in 2025 to streamline operations between its pharmaceutical and medical device segments, improving supply chain efficiency amid rising demand for healthcare consumables.[web:previous]